Evidence supporting the use of: Pelargonium (unspecified)
For the health condition: Influenza

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Pelargonium, particularly the species Pelargonium sidoides (commonly known as Umckaloabo), has been studied for its effects on respiratory tract infections, including influenza. Several clinical trials and systematic reviews have evaluated standardized extracts of Pelargonium sidoides root, showing modest efficacy in reducing the duration and severity of symptoms associated with acute bronchitis and, to a lesser extent, influenza-like illnesses. The mechanism is thought to involve immunomodulatory, antiviral, and antibacterial properties, including stimulation of interferon production and inhibition of viral attachment.

A 2008 Cochrane review and subsequent meta-analyses found moderate-quality evidence that Pelargonium sidoides extract may reduce the severity and duration of acute respiratory infections in adults and children. However, most studies have focused on bronchitis and the common cold; direct evidence in laboratory-confirmed influenza is limited, though some trials include patients with influenza-like illness (ILI). The European Medicines Agency (EMA) acknowledges its traditional use for relieving symptoms of common cold and acute bronchitis, but scientific evidence for influenza specifically is less robust.

In summary, while Pelargonium is not a replacement for antiviral therapy or vaccination, there is moderate scientific support—primarily for Pelargonium sidoides—for its use in relieving respiratory symptoms that can overlap with influenza, though evidence specifically for influenza is less definitive.

More about Pelargonium (unspecified)
More about Influenza

Products containing Pelargonium (unspecified)

We currently have no products on Vitabase that contain this ingredient.